Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 0.1% Higher – Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares traded up 0.1% during mid-day trading on Wednesday . The stock traded as high as $11.99 and last traded at $11.95. 236,477 shares were traded during mid-day trading, a decline of 85% from the average session volume of 1,536,873 shares. The stock had previously closed at $11.94.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research report on Monday. They set a “sell” rating for the company.

Tonix Pharmaceuticals Trading Down 0.2 %

The firm has a 50 day moving average price of $29.36 and a two-hundred day moving average price of $25.32. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a market cap of $22.28 million, a price-to-earnings ratio of 0.00 and a beta of 2.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, beating the consensus estimate of ($203.00) by $180.00. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. Commonwealth Equity Services LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 120,292 shares of the company’s stock, valued at approximately $40,000. Commonwealth Equity Services LLC owned approximately 6.43% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.